Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association

Pulmonary embolism (PE) represents the third leading cause of cardiovascular mortality. The technological landscape for management of acute intermediate- and high-risk PE is rapidly evolving. Two interventional devices using pharmacomechanical means to recanalize the pulmonary arteries have recently...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2019-11, Vol.140 (20), p.e774-e801
Main Authors: Giri, Jay, Sista, Akhilesh K, Weinberg, Ido, Kearon, Clive, Kumbhani, Dharam J, Desai, Nimesh D, Piazza, Gregory, Gladwin, Mark T, Chatterjee, Saurav, Kobayashi, Taisei, Kabrhel, Christopher, Barnes, Geoffrey D
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3097-30572c0ab2d33cc4819fcbd0ae1a8ef59eb3dd7767f7fdf96067e41b8ffbed7f3
cites cdi_FETCH-LOGICAL-c3097-30572c0ab2d33cc4819fcbd0ae1a8ef59eb3dd7767f7fdf96067e41b8ffbed7f3
container_end_page e801
container_issue 20
container_start_page e774
container_title Circulation (New York, N.Y.)
container_volume 140
creator Giri, Jay
Sista, Akhilesh K
Weinberg, Ido
Kearon, Clive
Kumbhani, Dharam J
Desai, Nimesh D
Piazza, Gregory
Gladwin, Mark T
Chatterjee, Saurav
Kobayashi, Taisei
Kabrhel, Christopher
Barnes, Geoffrey D
description Pulmonary embolism (PE) represents the third leading cause of cardiovascular mortality. The technological landscape for management of acute intermediate- and high-risk PE is rapidly evolving. Two interventional devices using pharmacomechanical means to recanalize the pulmonary arteries have recently been cleared by the US Food and Drug Administration for marketing, and several others are in various stages of development. The purpose of this document is to clarify the current state of endovascular interventional therapy for acute PE and to provide considerations for evidence development for new devices that will define which patients with PE would derive the greatest net benefit from their use in various clinical settings. First, definitions and limitations of commonly used risk stratification tools for PE are reviewed. An adjudication of risks and benefits of available interventional therapies for PE follows. Next, considerations for optimal future evidence development in this field are presented in the context of the current US regulatory framework. Finally, the document concludes with a discussion of the pros and cons of the rapidly expanding PE response team model of care delivery.
doi_str_mv 10.1161/CIR.0000000000000707
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2301443413</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2301443413</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3097-30572c0ab2d33cc4819fcbd0ae1a8ef59eb3dd7767f7fdf96067e41b8ffbed7f3</originalsourceid><addsrcrecordid>eNp9kc1OxCAUhYnRxPHnDVywdFOF0papu2YcdRKjxp91Q-klg9JSgY7xxXw-mRkXxoVsyOWe71xyD0InlJxRWtDz2eLxjPw-nPAdNKF5miVZzspdNImPZcJZmu6jA-9fY1kwnk_Q16IP4FbQB217YfDzEpwYNHisrMOVHAPgh9F0sek-8bxrrNG-u8Cz0bkI4acgwuix6Fv84HQv9WB-2LAEfAkrMHbo1kqr8J2NJZ6vdAu9hAtc4Sep16OVlhsn2CivnO02eNWB01L0-AaEC7jy3kot1j89QntKGA_HP_chermaP89uktv768Wsuk0kIyVPGMl5Kolo0pYxKbMpLZVsWiKAiimovISGtS3nBVdctaosSMEho81UqQZartghOt36Ds6-j-BD3WkvwRjRgx19nTJCs4xllEVptpVKZ713oOrB6S5uraakXsdUx5jqvzFFbLrFPqyJSfg3M36Aq5cgTFj-j34D21ObCQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2301443413</pqid></control><display><type>article</type><title>Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association</title><source>Free E-Journal (出版社公開部分のみ）</source><creator>Giri, Jay ; Sista, Akhilesh K ; Weinberg, Ido ; Kearon, Clive ; Kumbhani, Dharam J ; Desai, Nimesh D ; Piazza, Gregory ; Gladwin, Mark T ; Chatterjee, Saurav ; Kobayashi, Taisei ; Kabrhel, Christopher ; Barnes, Geoffrey D</creator><creatorcontrib>Giri, Jay ; Sista, Akhilesh K ; Weinberg, Ido ; Kearon, Clive ; Kumbhani, Dharam J ; Desai, Nimesh D ; Piazza, Gregory ; Gladwin, Mark T ; Chatterjee, Saurav ; Kobayashi, Taisei ; Kabrhel, Christopher ; Barnes, Geoffrey D ; On behalf of the American Heart Association Council on Peripheral Vascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; and Council on Cardiovascular Surgery and Anesthesia</creatorcontrib><description>Pulmonary embolism (PE) represents the third leading cause of cardiovascular mortality. The technological landscape for management of acute intermediate- and high-risk PE is rapidly evolving. Two interventional devices using pharmacomechanical means to recanalize the pulmonary arteries have recently been cleared by the US Food and Drug Administration for marketing, and several others are in various stages of development. The purpose of this document is to clarify the current state of endovascular interventional therapy for acute PE and to provide considerations for evidence development for new devices that will define which patients with PE would derive the greatest net benefit from their use in various clinical settings. First, definitions and limitations of commonly used risk stratification tools for PE are reviewed. An adjudication of risks and benefits of available interventional therapies for PE follows. Next, considerations for optimal future evidence development in this field are presented in the context of the current US regulatory framework. Finally, the document concludes with a discussion of the pros and cons of the rapidly expanding PE response team model of care delivery.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/CIR.0000000000000707</identifier><language>eng</language><publisher>by the American College of Cardiology Foundation and the American Heart Association, Inc</publisher><ispartof>Circulation (New York, N.Y.), 2019-11, Vol.140 (20), p.e774-e801</ispartof><rights>2019 by the American College of Cardiology Foundation and the American Heart Association, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3097-30572c0ab2d33cc4819fcbd0ae1a8ef59eb3dd7767f7fdf96067e41b8ffbed7f3</citedby><cites>FETCH-LOGICAL-c3097-30572c0ab2d33cc4819fcbd0ae1a8ef59eb3dd7767f7fdf96067e41b8ffbed7f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,783,787,27936,27937</link.rule.ids></links><search><creatorcontrib>Giri, Jay</creatorcontrib><creatorcontrib>Sista, Akhilesh K</creatorcontrib><creatorcontrib>Weinberg, Ido</creatorcontrib><creatorcontrib>Kearon, Clive</creatorcontrib><creatorcontrib>Kumbhani, Dharam J</creatorcontrib><creatorcontrib>Desai, Nimesh D</creatorcontrib><creatorcontrib>Piazza, Gregory</creatorcontrib><creatorcontrib>Gladwin, Mark T</creatorcontrib><creatorcontrib>Chatterjee, Saurav</creatorcontrib><creatorcontrib>Kobayashi, Taisei</creatorcontrib><creatorcontrib>Kabrhel, Christopher</creatorcontrib><creatorcontrib>Barnes, Geoffrey D</creatorcontrib><creatorcontrib>On behalf of the American Heart Association Council on Peripheral Vascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; and Council on Cardiovascular Surgery and Anesthesia</creatorcontrib><title>Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association</title><title>Circulation (New York, N.Y.)</title><description>Pulmonary embolism (PE) represents the third leading cause of cardiovascular mortality. The technological landscape for management of acute intermediate- and high-risk PE is rapidly evolving. Two interventional devices using pharmacomechanical means to recanalize the pulmonary arteries have recently been cleared by the US Food and Drug Administration for marketing, and several others are in various stages of development. The purpose of this document is to clarify the current state of endovascular interventional therapy for acute PE and to provide considerations for evidence development for new devices that will define which patients with PE would derive the greatest net benefit from their use in various clinical settings. First, definitions and limitations of commonly used risk stratification tools for PE are reviewed. An adjudication of risks and benefits of available interventional therapies for PE follows. Next, considerations for optimal future evidence development in this field are presented in the context of the current US regulatory framework. Finally, the document concludes with a discussion of the pros and cons of the rapidly expanding PE response team model of care delivery.</description><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kc1OxCAUhYnRxPHnDVywdFOF0papu2YcdRKjxp91Q-klg9JSgY7xxXw-mRkXxoVsyOWe71xyD0InlJxRWtDz2eLxjPw-nPAdNKF5miVZzspdNImPZcJZmu6jA-9fY1kwnk_Q16IP4FbQB217YfDzEpwYNHisrMOVHAPgh9F0sek-8bxrrNG-u8Cz0bkI4acgwuix6Fv84HQv9WB-2LAEfAkrMHbo1kqr8J2NJZ6vdAu9hAtc4Sep16OVlhsn2CivnO02eNWB01L0-AaEC7jy3kot1j89QntKGA_HP_chermaP89uktv768Wsuk0kIyVPGMl5Kolo0pYxKbMpLZVsWiKAiimovISGtS3nBVdctaosSMEho81UqQZartghOt36Ds6-j-BD3WkvwRjRgx19nTJCs4xllEVptpVKZ713oOrB6S5uraakXsdUx5jqvzFFbLrFPqyJSfg3M36Aq5cgTFj-j34D21ObCQ</recordid><startdate>20191112</startdate><enddate>20191112</enddate><creator>Giri, Jay</creator><creator>Sista, Akhilesh K</creator><creator>Weinberg, Ido</creator><creator>Kearon, Clive</creator><creator>Kumbhani, Dharam J</creator><creator>Desai, Nimesh D</creator><creator>Piazza, Gregory</creator><creator>Gladwin, Mark T</creator><creator>Chatterjee, Saurav</creator><creator>Kobayashi, Taisei</creator><creator>Kabrhel, Christopher</creator><creator>Barnes, Geoffrey D</creator><general>by the American College of Cardiology Foundation and the American Heart Association, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20191112</creationdate><title>Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association</title><author>Giri, Jay ; Sista, Akhilesh K ; Weinberg, Ido ; Kearon, Clive ; Kumbhani, Dharam J ; Desai, Nimesh D ; Piazza, Gregory ; Gladwin, Mark T ; Chatterjee, Saurav ; Kobayashi, Taisei ; Kabrhel, Christopher ; Barnes, Geoffrey D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3097-30572c0ab2d33cc4819fcbd0ae1a8ef59eb3dd7767f7fdf96067e41b8ffbed7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giri, Jay</creatorcontrib><creatorcontrib>Sista, Akhilesh K</creatorcontrib><creatorcontrib>Weinberg, Ido</creatorcontrib><creatorcontrib>Kearon, Clive</creatorcontrib><creatorcontrib>Kumbhani, Dharam J</creatorcontrib><creatorcontrib>Desai, Nimesh D</creatorcontrib><creatorcontrib>Piazza, Gregory</creatorcontrib><creatorcontrib>Gladwin, Mark T</creatorcontrib><creatorcontrib>Chatterjee, Saurav</creatorcontrib><creatorcontrib>Kobayashi, Taisei</creatorcontrib><creatorcontrib>Kabrhel, Christopher</creatorcontrib><creatorcontrib>Barnes, Geoffrey D</creatorcontrib><creatorcontrib>On behalf of the American Heart Association Council on Peripheral Vascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; and Council on Cardiovascular Surgery and Anesthesia</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giri, Jay</au><au>Sista, Akhilesh K</au><au>Weinberg, Ido</au><au>Kearon, Clive</au><au>Kumbhani, Dharam J</au><au>Desai, Nimesh D</au><au>Piazza, Gregory</au><au>Gladwin, Mark T</au><au>Chatterjee, Saurav</au><au>Kobayashi, Taisei</au><au>Kabrhel, Christopher</au><au>Barnes, Geoffrey D</au><aucorp>On behalf of the American Heart Association Council on Peripheral Vascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; and Council on Cardiovascular Surgery and Anesthesia</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><date>2019-11-12</date><risdate>2019</risdate><volume>140</volume><issue>20</issue><spage>e774</spage><epage>e801</epage><pages>e774-e801</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><abstract>Pulmonary embolism (PE) represents the third leading cause of cardiovascular mortality. The technological landscape for management of acute intermediate- and high-risk PE is rapidly evolving. Two interventional devices using pharmacomechanical means to recanalize the pulmonary arteries have recently been cleared by the US Food and Drug Administration for marketing, and several others are in various stages of development. The purpose of this document is to clarify the current state of endovascular interventional therapy for acute PE and to provide considerations for evidence development for new devices that will define which patients with PE would derive the greatest net benefit from their use in various clinical settings. First, definitions and limitations of commonly used risk stratification tools for PE are reviewed. An adjudication of risks and benefits of available interventional therapies for PE follows. Next, considerations for optimal future evidence development in this field are presented in the context of the current US regulatory framework. Finally, the document concludes with a discussion of the pros and cons of the rapidly expanding PE response team model of care delivery.</abstract><pub>by the American College of Cardiology Foundation and the American Heart Association, Inc</pub><doi>10.1161/CIR.0000000000000707</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 2019-11, Vol.140 (20), p.e774-e801
issn 0009-7322
1524-4539
language eng
recordid cdi_proquest_miscellaneous_2301443413
source Free E-Journal (出版社公開部分のみ）
title Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-13T07%3A16%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interventional%20Therapies%20for%20Acute%20Pulmonary%20Embolism:%20Current%20Status%20and%20Principles%20for%20the%20Development%20of%20Novel%20Evidence:%20A%20Scientific%20Statement%20From%20the%20American%20Heart%20Association&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=Giri,%20Jay&rft.aucorp=On%20behalf%20of%20the%20American%20Heart%20Association%20Council%20on%20Peripheral%20Vascular%20Disease;%20Council%20on%20Arteriosclerosis,%20Thrombosis%20and%20Vascular%20Biology;%20Council%20on%20Cardiopulmonary,%20Critical%20Care,%20Perioperative%20and%20Resuscitation;%20and%20Council%20on%20Cardiovascular%20Surgery%20and%20Anesthesia&rft.date=2019-11-12&rft.volume=140&rft.issue=20&rft.spage=e774&rft.epage=e801&rft.pages=e774-e801&rft.issn=0009-7322&rft.eissn=1524-4539&rft_id=info:doi/10.1161/CIR.0000000000000707&rft_dat=%3Cproquest_cross%3E2301443413%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3097-30572c0ab2d33cc4819fcbd0ae1a8ef59eb3dd7767f7fdf96067e41b8ffbed7f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2301443413&rft_id=info:pmid/&rfr_iscdi=true